Activity of the new cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa isolates from chronically-infected cystic fibrosis patients

Clinical Microbiology and Infection

Volumn 16, Issue 9, 2010, Pages 1482-1487

  Zamorano, L ^a   Juan, C ^a   Fernandez Olmos A ^b   Ge, Y ^c   Canton R ^b   Oliver, A ^a  

^a HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

^c Calixa Therapeutics Inc   (United States)

Author keywords

Antibiotic resistance; Cephalosporins; Cystic fibrosis; Pseudomonas aeruginosa

Indexed keywords

CEFEPIME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CXA 101; FR 254205; FR 264205; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TOBRAMYCIN; UNCLASSIFIED DRUG;

ADOLESCENT; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BROTH DILUTION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS RESISTANCE; CYSTIC FIBROSIS; DRUG EFFICACY; HUMAN; INFANT; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PRESCHOOL CHILD; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SCHOOL CHILD; SPAIN;

PSEUDOMONAS AERUGINOSA;

EID: 77955637131     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2010.03130.x     Document Type: Article

References (35)

1. Lyczak JB, Cannon CL, Pier GB. Lung infections associated with cystic fibrois. Clin Microbiol Rev 2002, 15:194-222.
2. Gibson RL, Burns JL, Rammsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003, 168:918-951.
3. Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis 2002, 34:634-640.
4. Oliver A, Cantón R, Campo P, Baquero F, Blázquez J. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 2000, 288:1251-1253.
5. Ciofu O, Riis B, Pressler P, Poulsen HP, Hoiby N. Ocurrence of hypermutable Pseudomonas aeruginosa in cystic fibrosis patients is associated with the oxidative stress caused by chronic lung inflamation. Antimicrob Agents Chemother 2005, 49:2276-2282.
6. Merlo CA, Boyle MP, Diener-West M, Marshall BC, Goss CH, Lechtzin N. Incidence and risk factors for multiple antibiotic-resistant Pseudomonas aeruginosa in cystic fibrosis. Chest 2007, 132:562-568.
7. Leichtzin N, John M, Irizarry R, Merlo C, Diette GB, Boyle MP. Outcomes of adults with cystic fibrosis infected with antibiotic-resistant Pseudomonas aeruginosa. Respiration 2006, 73:27-33.
8. Ballesteros S, Fernández-Rodríguez A, Villaverde R, Escobar H, Pérez-Díaz JC, Baquero F. Carbapenem resistance in Pseudomonas aeruginosa from cystic fibrosis patients. J Antimicrob Chemother 1996, 38:39-45.
9. Bagge N, Ciofu O, Hentzer M, Campbell JI, Givskov M, Hoiby N. Constitutive high expression of chromosomal β-lactamase in Pseudomonas aeruginosa caused by a new insertion sequence (IS1669) located in ampD. Antimicrob Agents Chemother 2002, 46:3406-3411.
10. Moya B, Döstch A, Juan C et al. B-lactam resistance response triggered by inactivation of a nonessential penicillin-binding protein. PLoS Pathog 2009, 5:e1000353.
11. Jalal S, Ciofu O, Hoiby N, Gotoh N, Wretlind B. Molecular mechanisms of fluoroquinolone resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob Agents Chemother 2000, 44:710-712.
12. Vogne C, Aires JR, Bailly C, Hocquet D, Plesiat P. Role of the multidrug efflux system MexXY in the emergence of moderate resistance to aminoglycosides among Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 2004, 48:1676-1680.
13. Foweraker JE, Laughton CR, Brown DF, Bilton D. Phenotypic variability of Pseudomonas aeruginosa in sputa from patients with acute infective exacerbation of cystic fibrosis and its impact on the validity of antimicrobial susceptibility testing. J Antimicrob Chemother 2005, 55:921-927.
14. Smith EE, Buckley DG, Wu Z. Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. Proc Natl Acad Sci USA 2006, 103:8487-8492.
15. Mena A, Smith EE, Burns JL. Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients is catalyzed by hypermutation. J Bacteriol 2008, 190:7910-7917.
16. Govan JR, Deretic V. Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev 1996, 60:539-574.
17. Parad RB, Gerard CJ, Zurakowski D, Nichols DP, Pier GB. Pulmonary outcome in cystic fibrosis is influenced primarily by mucoid Pseudomonas aeruginosa infection and immune status and only modestly by genotype. Infect Immun 1999, 67:4744-4750.
18. Yu H, Hanes M, Chrisp CE, Boucher JC, Deretic V. Microbial pathogenesis in cystic fibrosis: pulmonary clearance of mucoid Pseudomonas aeruginosa and inflammation in a mouse model of repeated respiratory challenge. Infect Immun 1998, 66:280-288.
19. Pedersen S, Kharazmi SA, Espersen F, Hoiby N. Pseudomonas aeruginosa alginate in cystic fibrosis sputum and the inflamatory response. Infect Immun 1990, 58:3363-3368.
20. Hatch RA, Schiller NL. Alginate lyase promotes diffusion of aminoglycosides through the extracellular polysaccharide of mucoid Pseudomonas aeruginosa. Antimicrob Agents Chemother 1998, 42:974-977.
21. Simpson JA, Smith SE, Dean RT. Scavenging by alginate of free radicals released by macrophages. Free Radic Biol Med 1989, 6:347-353.
22. Häuβler S, Tümmler B, Weissbrodt H, Rohde M, Steinmetz I. Small colony variants of Pseudomonas aeruginosa in cystic fibrosis. Clin Infect Dis 1999, 29:621-625.
23. Takeda S, Ishii Y, Hatano K, Tateda K, Yamaguchi K. Stability of FR264205 against AmpC β-lactamase of Pseudomonas aeruginosa. Int J Antimicrob Agents 2007, 30:443-445.
24. Takeda S, Nakai T, Wakai Y, Ikeda F, Hatano K. In vitro and In vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2007, 51:826-830.
25. Performance standards for antimicrobial susceptibility testing 2008, Clinical and Laboratory Standards Institute (CLSI), vol. 28, no. 3, 18th informational supplement. M100-S18, Wayne, PA, Clinical and Laboratory Standards Institute
26. Ge Y, Liao S. CXA-101 (CXA) population PK analysis and Monte Carlo (MC) simulation for PK/PD target attainment and dose regimen selection. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Abstract F1-2003. San Francisco, USA, 12-15 September 2009
27. Taccetti G, Campana S, Festini F, Mascherini M, Döring G. Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients. Eur Respir J 2005, 26:458-461.
28. Cantón R, Cobos N, de Gracia J. Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients. Clin Microbiol Infect 2005, 11:690-703.
29. Henwood CJ, Livermore DM, James D, Warner M. Antimicrobial susceptibility of Pseudomonas aeruginosa: results of a UK survey and evaluation of the British Society for Antimicrobial Chemotherapy disc susceptibility test. J Antimicrob Chemother 2001, 47:789-799. the Pseudomonas study group
30. Chen Y, Garber E, Zhao Q. In vitro activity of doripenem (S-4661) against multidrug-resistant gram-negative bacilli isolated from patients with cystic fibrosis. Antimicrob Agents Chemother 2005, 49:2510-2511.
31. Mushtaq S, Ge Y, Livermore DM. Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential. Antimicrob Agents Chemother 2005, 48:3086-3092.
32. Moya B, Zamorano L, Juan C, Pérez JL, Ge Y, Oliver A. Activity of a new cephalosporin, CXA-101 (FR264205) against β-lactom-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of Intensive Care Unit patients: Antimicrob Agents Chemother. 2010, 10.1128/AAC.01104-09, doi
33. Juan C, Zamorano L, Pérez JL, Ge Y, Oliver A. Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains. Antimicrob Agents Chemother 2009, 54:846-851. on behalf of the Spanish Group for the Study of Pseudomonas and REIPI
34. Livermore DM, Mushtaq S, Ge Y, Wagner M. Activity of cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa and Burkholderhia cepacia group strains and isolates. Int J Antimicrob Agents 2009, 34:402-406.
35. Brown NP, Pillar CM, Sham DF, Ge Y. Activity profile of CXA-101 and CXA-101/tazobactam against target Gram-positive and Gram-negative pathogens. Abstract F1-1986. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, Ca, 2009